Bristol-Pfizer's blood thinner Eliquis wins FDA approval

Bristol-Myers Squibb and Pfizer's Eliquis, or apixaban, has been approved by the FDA to reduce the risk of strokes and blood clots for people with atrial fibrillation. The anticoagulant, however, should not be given to patients with artificial heart valves or those with atrial fibrillation due to heart valve problems, the FDA said. Eliquis, which has been approved in Europe, is seen has having the potential to become a blockbuster.

View Full Article in:

New York Times (tiered subscription model), The · USA Today

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ